Skip to main navigation

Overview
News & Events
- News Releases
- Events & Presentations
Governance
Financials
- SEC Filings
- IRS Form 8937
Stock
Resources

News Releases

Year

07 Mar '23

Carisma Therapeutics Closes Merger with Sesen Bio

21 Feb '23

Leading Independent Proxy Advisory Firm Glass Lewis Joins ISS in Recommending That Sesen Bio Stockholders Vote “FOR” All Proposals to Approve Pending Merger With Carisma

16 Feb '23

Leading Independent Proxy Advisory Firm ISS Recommends Sesen Bio Stockholders Vote “FOR” All Proposals at March 2 Special Meeting

16 Feb '23

Sesen Bio to Host Webcast with Carisma Therapeutics to Discuss Pending Merger

15 Feb '23

BML, One of Sesen Bio’s Top Stockholders, Announces Support for Pending Merger with Carisma Therapeutics

14 Feb '23

Sesen Bio and Carisma Therapeutics Announce Increased Special Cash Dividend and Stockholder Support for Pending Merger

07 Feb '23

Carisma Therapeutics Appoints Moderna CSO of External Research Ventures, Lin Guey, to Scientific Advisory Board

02 Feb '23

Sesen Bio Files Investor Presentation in Connection with Pending Carisma Therapeutics Merger

31 Jan '23

Carisma Therapeutics Appoints Leading Solid Tumor Immunotherapy Expert Padmanee Sharma, MD, PhD to Scientific Advisory Board

26 Jan '23

Sesen Bio Reiterates Confidence that Pending Merger with Carisma is in Best Interests of Stockholders

Pagination

First page
Previous page
Page 1
Page 2
Current page 3
Page 4
Next page
Last page

Displaying 21 - 30 of 32

Site - Investor Tools

Print Page
Email Alerts
RSS Feeds
IR Contact

Request Email Alerts

© 2023 Carisma Therapeutics Inc. All rights reserved.